整理 | GLP1减重宝典内容团队 近日，RNA药物研发公司Protagonist Therapeutics宣布，已选定 PN-477 作为治疗肥胖的主要开发候选药物。这是一款潜力巨大的三重 激动剂肽，靶向 GLP-1、GIP 和胰高血糖素（GCG）受体，可通过口服或皮下注射给药，兼具疗效与便利性。 PN-477 旨在实现显著的体重减轻、改善胃肠耐受性，以及优化脂肪与瘦体重的比例，同时提供每日一次口服与每周一次注射的灵活治 疗方式。 | | 1H 2025 | | 2H 2025 | 1H 2026 | | 2H 2026 | | --- | --- | --- | --- | --- | --- | --- | | Rusfertide | * PV day V · VERIFY topline results2J · ASCO VERIFY plenary | | * NDA filing4 * ASH Meeting® | · Medical Conferences | | * US Approval (PV) | | | presentation3/ | | | | | | | | * Medical ...

Post-ASCO Update: Phase 3 VERIFY Study Results Protagonist Therapeutics, Inc. Newark, CA June 2, 2025 Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business stra ...